KaioM BioScience Co., Ltd.
株式会社カイオム・バイオサイエンス
Chiome Bioscience Inc.
Alias
Chiome Bioscience
Alias
Japan
Antibody technology development
Therapeutic antibody research and development
Clinical development of antibody-based therapeutics
Antibody drug discovery
ADC and multi-specific antibody development
ADLib® antibody platform technology
Pipeline development
Technology development
Platform provision
ADLib® system services
6th Floor, Sumitomo Real Estate Nishishinjuku Building, 12-1 Honmachi 3-chome, Shibuya-ku, Tokyo 151-0071, Japan
Masamichi Koike
1,085,523,000 JPY (10 100 millionJPY)
47 people
Company name
Group
Parent
Subsidiary
Customer
Supplier
Alliance
Bank
Shareholder
Loading...
Loading the relationship graph...
18 entries
| Date | Description |
|---|
| 2005 |
KaioM BioScience Co., Ltd. is a bio-venture founded in 2005. Since its establishment, it has been developing antibody-related technologies and drug discovery business, continuing to this day. |
| 2005-02 |
Established KaioM BioScience Co., Ltd. (capital 10,000 thousand yen) |
| 2005-04 |
Entered into a joint research agreement with RIKEN to commercialize the ADLib® system and commenced research activities. |
| 2005-07 |
Obtained exclusive implementation rights with sublicensing to third parties for the commercialization of the foundational technology (ADLib® system) from RIKEN and the Japan Science and Technology Agency (JST). |
| 2009-10 |
Relocated headquarters to Shinjuku-ku, Tokyo. |
| 2010-08 |
Signed a paid transfer agreement for patents related to the foundational technology (ADLib® system) with the Japan Science and Technology Agency (JST). |
| 2011-12 |
Listed shares on the Tokyo Stock Exchange Mothers market. |
| 2013-05 |
Relocated main office to Shibuya-ku, Tokyo. |
| 2013-12 |
Acquired a majority of the issued shares of Livetech Inc. and made it a subsidiary. |
| 2015-07 |
Absorbed Livetech Inc. through a merger. |
| 2015-10 |
Invested capital in Ibeck Inc. |
| 2017-02 |
Investment in Trans Chromosomics Inc. |
| 2017-09 |
Signed a licensing agreement with Swiss company ADC Therapeutics for the development of LIV-1205 ADC. |
| 2018-12 |
Signed a transfer agreement for the cancer therapeutic candidate antibody Tb535H (now CBA-1535) and the antibody modification technology Tribody™. |
| 2020-07 |
Commencement of Phase 1 clinical trial of our first clinical development product, cancer therapeutic candidate antibody CBA-1205. |
| 2021-01 |
Signed a licensing agreement with Shanghai Henlius Biotech Co., Ltd. (headquarters, Shanghai) for the development, manufacturing, and sales of cancer therapeutic antibodies LIV-2008 and LIV-2008b in the Greater China region (January 2023, license expired). |
| 2022-04 |
Transitioned from the Tokyo Stock Exchange Mothers market to the Growth market due to a review of market classifications. |
| 2022-06 |
Commencement of the first clinical trial of Tribody™ worldwide, the Phase 1 clinical trial of our clinical development product, cancer therapeutic candidate antibody CBA-1535. |
6011101054960
| Trade name | 株式会社カイオム・バイオサイエンス |
|---|
| Trade name (kana) | カイオムバイオサイエンス |
|---|
| Name in English | |
|---|
| Corporation type | 301 |
|---|
| Address | 〒151-0071 東京都渋谷区本町３丁目１２番１号 |
|---|
| Postal code | 1510071 |
|---|
| Prefecture code | 13 |
|---|
| City code | 113 |
|---|
| Address outside Japan | |
|---|
| Prefecture in English | |
|---|
| City in English | |
|---|
| Address outside Japan in English | |
|---|
| Corporate number assignment date | 2015-10-05 |
|---|
| Update date | 2023-08-07 |
|---|
| Change date | 2015-10-05 |
|---|
| Registry closure date | |
|---|
| Reason for registry closure | |
|---|
| Successor corporate number | |
|---|
| Details of the change | |
|---|
| Latest record | 1 |
|---|
| Excluded from search | 0 |
|---|
| Processing type | 01 |
|---|
| Correction type | 1 |
|---|
| Trade name image ID | |
|---|
| Address image ID | |
|---|
| Sequence number | 2100376 |
|---|
Source: National Tax Agency Corporate Number Publication Site, basic three items
6011101054960
| Corporate number | 6011101054960 |
|---|
| Trade name | 株式会社カイオム・バイオサイエンス |
|---|
| Trade name (kana) | カイオムバイオサイエンス |
|---|
| Trade name (alphabet) | |
|---|
| Registry closure date | |
|---|
| Reason for registry closure | |
|---|
| Registered address | 東京都渋谷区本町３丁目１２番１号 |
|---|
| Postal code | 1510071 |
|---|
| Prefecture | 東京都 |
|---|
| Prefecture code | 13 |
|---|
| City or district | 渋谷区 |
|---|
| City code | 113 |
|---|
| Street address | 本町３丁目１２番１号 |
|---|
| Organisation type | 301 |
|---|
| Processing type | 01 |
|---|
| Correction type | 1 |
|---|
| Status | |
|---|
| Representative | 代表取締役社長 小池 正道 |
|---|
| Capital | 1085523000 |
|---|
| Employees | 49 |
|---|
| Employees (male) | |
|---|
| Employees (female) | |
|---|
| Business summary | |
|---|
| Website URL | |
|---|
| Year founded | |
|---|
| Business category | |
|---|
| Date established | |
|---|
| Unified government qualification - grade | |
|---|
| Unified government qualification - business items | |
|---|
| Update date | 2023-08-07 |
|---|
| Key information | 6011101054960 |
|---|
Source: gBizINFO (Ministry of Economy, Trade and Industry)
2026-09-23 01:40 (Model: ggml-org/gpt-oss-20b )
